Oppenheimer Weighs in on Mustang Bio Inc’s FY2017 Earnings (MBIO)

Mustang Bio Inc (NASDAQ:MBIO) – Research analysts at Oppenheimer issued their FY2017 earnings estimates for Mustang Bio in a research note issued on Wednesday. Oppenheimer analyst M. Breidenbach forecasts that the company will earn ($0.87) per share for the year. Oppenheimer currently has a “Outperform” rating and a $18.00 target price on the stock. Oppenheimer also issued estimates for Mustang Bio’s Q4 2017 earnings at ($0.24) EPS, Q1 2018 earnings at ($0.25) EPS, Q2 2018 earnings at ($0.27) EPS, Q3 2018 earnings at ($0.28) EPS, Q4 2018 earnings at ($0.32) EPS, FY2018 earnings at ($1.12) EPS, Q1 2019 earnings at ($0.32) EPS, Q2 2019 earnings at ($0.32) EPS, Q3 2019 earnings at ($0.30) EPS, FY2019 earnings at ($1.25) EPS, FY2020 earnings at ($1.36) EPS and FY2021 earnings at ($1.02) EPS.

Separately, CIBC initiated coverage on shares of Mustang Bio in a report on Thursday, December 21st. They issued an “outperform” rating and a $18.00 target price on the stock.

Shares of Mustang Bio (NASDAQ MBIO) opened at $11.76 on Monday. Mustang Bio has a fifty-two week low of $8.06 and a fifty-two week high of $13.35.

TRADEMARK VIOLATION WARNING: “Oppenheimer Weighs in on Mustang Bio Inc’s FY2017 Earnings (MBIO)” was originally posted by Community Financial News and is owned by of Community Financial News. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright legislation. The original version of this article can be viewed at https://www.com-unik.info/2017/12/27/oppenheimer-weighs-in-on-mustang-bio-incs-fy2017-earnings-mbio.html.

About Mustang Bio

Mustang Bio, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to utilize the power of the patient’s own immune system to eliminate cancer cells. It seeks to acquire rights to technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development and eventually either out-licensing or bringing the technologies to market.

Earnings History and Estimates for Mustang Bio (NASDAQ:MBIO)

Receive News & Ratings for Mustang Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mustang Bio and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit